Blood biomarkers for cancer detection
Pro Research Analysisby 
Searched over 200M research papers
Blood-Based Biomarkers for Cancer Detection: Key Types and Their Clinical Potential
Blood-based biomarkers are transforming cancer detection by offering noninvasive, accessible, and real-time insights into tumor presence and progression. These biomarkers can be found in various forms in the blood, each providing unique information for early diagnosis, risk assessment, and monitoring.
Circulating Tumor DNA (ctDNA) and Cell-Free Nucleic Acids
Circulating tumor DNA (ctDNA) consists of small fragments of DNA released from cancer cells into the bloodstream. ctDNA detection is a promising approach for early cancer diagnosis, monitoring treatment response, and guiding therapy decisions. It is noninvasive and can be used repeatedly, making it suitable for tracking tumor dynamics over time. However, further validation is needed before ctDNA can be widely used in clinical practice Han2017Marrugo-Ramírez2018Kalnina2015.
Cell-free nucleic acids, including long noncoding RNAs (lncRNAs), are also being explored as blood biomarkers. Abnormal levels of circulating lncRNAs have been linked to the presence of tumors, and over 50 different lncRNAs have shown potential for early cancer diagnosis, prognosis, and even as therapeutic targets Badowski2022Kalnina2015.
Circulating Tumor Cells (CTCs) and Tumor-Educated Platelets (TEPs)
Circulating tumor cells (CTCs) are cancer cells that have detached from the primary tumor and entered the bloodstream. Their detection can aid in early diagnosis, prognosis, and monitoring of metastasis. CTCs are a key component of liquid biopsy strategies, providing valuable information about tumor characteristics without the need for invasive tissue biopsies Mamdani2017Marrugo-Ramírez2018Kalnina2015.
Tumor-educated platelets (TEPs) are another emerging biomarker. Platelets can absorb tumor-derived molecules, and their RNA profiles change in response to cancer. TEP RNA signatures have been shown to distinguish cancer patients from those with noncancerous diseases and may provide information on tumor type and location. TEPs could complement other blood-based biomarkers for early detection and disease monitoring Best2018Mamdani2017.
Protein Biomarkers and Autoantibodies
Blood protein biomarkers, such as tumor-associated antigens, autoantibodies, and exosomal proteins, are widely studied for cancer detection. Panels of protein biomarkers can improve risk assessment and screening accuracy, especially when combined with clinical risk models. For example, a four-marker protein panel significantly improved lung cancer risk assessment compared to standard screening criteria Fahrmann2022Huang2022Das2023+1 MORE.
Autoantibodies against tumor-associated antigens are also being investigated as early indicators of cancer, as they can appear before clinical symptoms develop Kalnina2015Huang2022.
Exosomes and Extracellular Vesicles
Exosomes are small vesicles released by tumor cells into the blood, carrying proteins, DNA, RNA, and other molecules. They reflect the genetic and molecular makeup of the tumor and can be used for early detection, monitoring treatment response, and assessing tumor heterogeneity Mamdani2017Kalnina2015Marrugo-Ramírez2018.
Multi-Analyte Approaches and Liquid Biopsy
Combining multiple types of blood biomarkers—such as gene mutations, proteins, and exosomes—can enhance the sensitivity and specificity of cancer detection. Multi-analyte tests like CancerSEEK aim to detect and localize various cancers at an early stage, potentially improving outcomes by enabling earlier intervention Kalinich2018Das2023Marrugo-Ramírez2018.
Liquid biopsy, which analyzes these biomarkers in blood, offers a noninvasive, repeatable, and cost-effective alternative to traditional tissue biopsies. It is especially valuable for tumors that are difficult to access or for patients who cannot undergo invasive procedures Mamdani2017Marrugo-Ramírez2018Das2023.
Conclusion
Blood-based biomarkers—including ctDNA, lncRNAs, CTCs, TEPs, protein panels, autoantibodies, and exosomes—are revolutionizing cancer detection and monitoring. These noninvasive tools offer earlier diagnosis, improved risk assessment, and real-time tracking of disease progression, with the potential to supplement or even replace traditional tissue biopsies in the future. Ongoing research and technological advances continue to improve their accuracy and clinical utility, bringing us closer to more effective and personalized cancer care Best2018Mamdani2017Kalinich2018+7 MORE.
Sources and full results
Most relevant research papers on this topic